Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial
Hedy L Kindler1, Silvia Novello2, Alessandra Bearz3, Giovanni L Ceresoli4, Joachim G J V Aerts5, James Spicer6, Paul Taylor7, Kristiaan Nackaerts8, Alastair Greystoke9, Ross Jennens10, Luana Calabrò11, Jacobus A Burgers12, Armando Santoro13,14, Susana Cedrés15, Piotr Serwatowski16, Santiago Ponce16, Jan P Van Meerbeeck17, Anna K Nowak18,19, George Blumenschein20, Jonathan M Siegel21
1Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA
2Department of Oncology, University of Turin, Orbassano, Turin, Italy
3Department of Medical Oncology and Immune-Related Cancers, CRO-IRCCS Centro di Riferimento Oncologico di Aviano, Aviano, Italy
4Department of Medical Oncology, Oncology Unit, Cliniche Humanitas Gavazzeni, Bergamo, Italy
5Department of Pulmonary Medicine, Erasmus MC Cancer Centre, Rotterdam, Netherlands
6Comprehensive Cancer Centre, King’s College London, London, UK
7Department of Medical Oncology, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK
8Laboratory of Respiratory Diseases and Thoracic Surgery, Department of Chronic Diseases and Metabolism, Universitair Ziekenhuis Leuven, KU Leuven, Leuven, Belgium
9Department of Medical Oncology, Northern Centre for Cancer Care, Newcastle upon Tyne, UK
10Epworth Cancer Services Clinical Institute, Epworth Healthcare, Richmond, VIC, Australia
11Department of Oncology, Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy
12Department of Thoracic Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
13Humanitas University, Milan, Italy
14Department of Medical Oncology and Hematology, IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy
15Department of Medical Oncology, University Hospital Vall d'Hebron, Barcelona, Spain
16Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
17Department of Thoracic Oncology, Antwerp University and University Hospital and European Reference Network for Rare or Low Prevalence Complex Disease (ERN-LUNG), Antwerp, Belgium
18Medical School, University of Western Australia, Perth, WA, Australia
19National Centre for Asbestos Related Diseases, Institute for Respiratory Health, Perth, WA, Australia
20Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
21Clinical Statistics Oncology, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
The Lancet Oncology
Tập 23
540-552
Thông tin tác giả